Apriem Advisors Acquires New Shares in Solventum Co. (NYSE:SOLV)

Apriem Advisors bought a new position in shares of Solventum Co. (NYSE:SOLV) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 5,046 shares of the company’s stock, valued at approximately $333,000.

Other institutional investors have also added to or reduced their stakes in the company. Modus Advisors LLC bought a new position in shares of Solventum in the 4th quarter worth $25,000. Stonebridge Financial Group LLC purchased a new position in Solventum in the fourth quarter valued at about $26,000. Crews Bank & Trust bought a new position in Solventum in the fourth quarter worth about $32,000. True Wealth Design LLC raised its holdings in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new stake in shares of Solventum in the 3rd quarter valued at about $35,000.

Solventum Stock Performance

Shares of SOLV stock opened at $83.83 on Thursday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a fifty day moving average of $71.92 and a 200 day moving average of $69.63. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday. Piper Sandler increased their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price objective for the company. Finally, Morgan Stanley upped their target price on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average target price of $71.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.